Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera

PLoS Neglected Tropical Diseases

Volumn 12, Issue 2, 2018, Pages

  Das, Soumita ^a   Angsantikul, Pavimol ^b   Le, Christine ^c   Bao, Denny ^a   Miyamoto, Yukiko ^c   Gao, Weiwei ^b   Zhang, Liangfang ^b   Eckmann, Lars ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CYCLIC AMP; GANGLIOSIDE; MACROGOL; MONOSIALOTETRAHEXOSYLGANGLIOSIDE; NANOPARTICLE; UNCLASSIFIED DRUG; GANGLIOSIDE GM1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRIFUGATION; CHOLERA; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ELECTROLYTE DISTURBANCE; ESCHERICHIA COLI; EVAPORATION; FEMALE; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; INTERVENTION STUDY; LIGHT SCATTERING; MALE; MAXIMUM BINDING CAPACITY; MOLECULAR WEIGHT; MORBIDITY; MORPHOLOGY; MORTALITY; MOUSE; NANOTECHNOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PARTICLE SIZE; SECRETION (PROCESS); SERODIAGNOSIS; SPECTROPHOTOMETRY; TRANSMISSION ELECTRON MICROSCOPY; VIBRIO CHOLERAE; ANIMAL; BINDING SITE; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PROCEDURES; SMALL INTESTINE; TUMOR CELL LINE;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CHOLERA; CHOLERA TOXIN; CYCLIC AMP; FEMALE; G(M1) GANGLIOSIDE; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; NANOTECHNOLOGY; VIBRIO CHOLERAE;

EID: 85044371840     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006266     Document Type: Article

References (47)

1. Gugnani HC, (1999) Some emerging food and water borne pathogens. J Commun Dis31:65–72. 10810592
2. (2013) Surveillance for foodborne disease outbreaks—United States, 2009–2010. MMWR Morb Mortal Wkly Rep62:41–47. 23344696
3. Chowdhury F, Rahman MA, Begum YA, Khan AI, Faruque AS, Saha NC, Baby NI, Malek MA, Kumar AR, Svennerholm AM, Pietroni M, Cravioto A, Qadri F, (2011) Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS Negl Trop Dis5:e999. doi: 10.1371/journal.pntd.0000999 21483709
4. Hirschhorn N, Kinzie JL, Sachar DB, Northrup RS, Taylor JO, Ahmad SZ, Phillips RA, (1968) Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med279:176–181. doi: 10.1056/NEJM196807252790402 4968807
5. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J, (2017) Cholera. Lancet390:1539–1549. doi: 10.1016/S0140-6736(17)30559-7 28302312
6. Atia AN, Buchman AL, (2009) Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol104:2596–2604. doi: 10.1038/ajg.2009.329 19550407
7. Wallace CK, Anderson PN, Brown TC, Khanra SR, Lewis GW, Pierce NF, Sanyal SN, Segre GV, Waldman RH, (1968) Optimal antibiotic therapy in cholera. Bull World Health Organ39:239–245. 4881071
8. Andersson DI, Hughes D, (2014) Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol12:465–478. doi: 10.1038/nrmicro3270 24861036
9. Spangler BD, (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev56:622–647. 1480112
10. Holmgren J, Lonnroth I, Mansson J, Svennerholm L, (1975) Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci U S A72:2520–2524. 1058471
11. Tsai B, Rapoport TA, (2002) Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. J Cell Biol159:207–216. doi: 10.1083/jcb.200207120 12403808
12. O’Neal CJ, Jobling MG, Holmes RK, Hol WG, (2005) Structural basis for the activation of cholera toxin by human ARF6-GTP. Science309:1093–1096. doi: 10.1126/science.1113398 16099990
13. Cassel D, Selinger Z, (1977) Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci U S A74:3307–3311. 198781
14. Kimberg DV, Field M, Gershon E, Henderson A, (1974) Effects of prostaglandins and cholera enterotoxin on intestinal mucosal cyclic AMP accumulation. Evidence against an essential role for prostaglandins in the action of toxin. J Clin Invest53:941–949. doi: 10.1172/JCI107635 4359941
15. Paton AW, Morona R, Paton JC, (2010) Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections. Bioeng Bugs1:172–177. doi: 10.4161/bbug.1.3.10665 21326923
16. Farokhzad OC, Langer R, (2009) Impact of nanotechnology on drug delivery. ACS Nano3:16–20. doi: 10.1021/nn900002m 19206243
17. Petros RA, DeSimone JM, (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov9:615–627. doi: 10.1038/nrd2591 20616808
18. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC, (2008) Self-assembled lipid—polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano2:1696–1702. doi: 10.1021/nn800275r 19206374
19. Fang RH, Luk BT, Hu CM, Zhang L, (2015) Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv Drug Deliv Rev90:69–80. doi: 10.1016/j.addr.2015.04.001 25868452
20. Hu CM, Fang RH, Copp J, Luk BT, Zhang L, (2013) A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol8:336–340. doi: 10.1038/nnano.2013.54 23584215
21. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC, (2009) PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials30:1627–1634. doi: 10.1016/j.biomaterials.2008.12.013 19111339
22. Lee KM, Park Y, Bari W, Yoon MY, Go J, Kim SC, Lee HI, Yoon SS, (2012) Activation of cholera toxin production by anaerobic respiration of trimethylamine N-oxide in Vibrio cholerae. J Biol Chem287:39742–39752. doi: 10.1074/jbc.M112.394932 23019319
23. Sawasvirojwong S, Srimanote P, Chatsudthipong V, Muanprasat C, (2013) An Adult Mouse Model of Vibrio cholerae-induced Diarrhea for Studying Pathogenesis and Potential Therapy of Cholera. PLoS Negl Trop Dis7:e2293. doi: 10.1371/journal.pntd.0002293 23826402
24. Copp JA, Fang RH, Luk BT, Hu CM, Gao W, Zhang K, Zhang L, (2014) Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci U S A111:13481–13486. doi: 10.1073/pnas.1412420111 25197051
25. Bouillot S, Attree I, Huber P, (2015) Pharmacological activation of Rap1 antagonizes the endothelial barrier disruption induced by exotoxins ExoS and ExoT of Pseudomonas aeruginosa. Infect Immun83:1820–1829. doi: 10.1128/IAI.00010-15 25690098
26. Cabrera A, Lepage JE, Sullivan KM, Seed SM, (2017) Vaxchora: A Single-Dose Oral Cholera Vaccine. Ann Pharmacother51:584–589. doi: 10.1177/1060028017698162 28622736
27. Focareta A, Paton JC, Morona R, Cook J, Paton AW, (2006) A recombinant probiotic for treatment and prevention of cholera. Gastroenterology130:1688–1695. doi: 10.1053/j.gastro.2006.02.005 16697733
28. Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S, (2001) Quality assurance criteria for probiotic bacteria. Am J Clin Nutr73:393S–398S. 11157347
29. Riglar DT, Giessen TW, Baym M, Kerns SJ, Niederhuber MJ, Bronson RT, Kotula JW, Gerber GK, Way JC, Silver PA, (2017) Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat Biotechnol35:653–658. doi: 10.1038/nbt.3879 28553941
30. Fishman PH, Pacuszka T, Orlandi PA, (1993) Gangliosides as receptors for bacterial enterotoxins. Adv Lipid Res25:165–187. 8396312
31. Pandita D, Kumar S, Lather V, (2015) Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today20:95–104. doi: 10.1016/j.drudis.2014.09.018 25277320
32. Li Y, Wu H, Yang X, Jia M, Huang Y, Lin J, Wu S, Hou Z, (2014) Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. Mol Pharm11:2915–2927. doi: 10.1021/mp500254j 24984984
33. Mandal B, Mittal NK, Balabathula P, Thoma LA, Wood GC, (2016) Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Eur J Pharm Sci81:162–171. doi: 10.1016/j.ejps.2015.10.021 26517962
34. Guo L, Chen B, Liu R, Xia G, Wang Y, Li X, Wei C, Wang X, Jiang H, (2015) Biocompatibility Assessment of Polyethylene Glycol-Poly L-Lysine-Poly Lactic-Co-Glycolic Acid Nanoparticles In Vitro and In Vivo. J Nanosci Nanotechnol15:3710–3719. 26504996
35. Makadia HK, Siegel SJ, (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel)3:1377–1397.
36. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C, (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn9:325–341. doi: 10.1586/erm.09.15 19435455
37. Ohashi K, Kabasawa T, Ozeki T, Okada H, (2009) One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release135:19–24. doi: 10.1016/j.jconrel.2008.11.027 19121349
38. Jung DS, Hwang TH, Park SB, Choi JW, (2013) Spray drying method for large-scale and high-performance silicon negative electrodes in Li-ion batteries. Nano Lett13:2092–2097. doi: 10.1021/nl400437f 23537321
39. Perry JL, Herlihy KP, Napier ME, Desimone JM, (2011) PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res44:990–998. doi: 10.1021/ar2000315 21809808
40. Moulari B, Beduneau A, Pellequer Y, Lamprecht A, (2014) Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release188:9–17. doi: 10.1016/j.jconrel.2014.05.046 24910194
41. Makhlof A, Werle M, Tozuka Y, Takeuchi H, (2011) A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release149:81–88. doi: 10.1016/j.jconrel.2010.02.001 20138935
42. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW, (2010) Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials31:3384–3394. doi: 10.1016/j.biomaterials.2010.01.042 20149435
43. Wu ZM, Zhou L, Guo XD, Jiang W, Ling L, Qian Y, Luo KQ, Zhang LJ, (2012) HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm425:1–8. doi: 10.1016/j.ijpharm.2011.12.055 22248666
44. Barea MJ, Jenkins MJ, Lee YS, Johnson P, Bridson RH, (2012) Encapsulation of Liposomes within pH Responsive Microspheres for Oral Colonic Drug Delivery. Int J Biomater2012:458712. doi: 10.1155/2012/458712 22792110
45. Moss J, Osborne JC, Jr.Fishman PH, Nakaya S, Robertson DC, (1981) Escherichia coli heat-labile enterotoxin. Ganglioside specificity and ADP-ribosyltransferase activity. J Biol Chem256:12861–12865. 6273411
46. Merritt EA, Sixma TK, Kalk KH, van Zanten BA, Hol WG, (1994) Galactose-binding site in Escherichia coli heat-labile enterotoxin (LT) and cholera toxin (CT). Mol Microbiol13:745–753. 7997185
47. Lee MS, Koo S, Jeong DG, Tesh VL, (2016) Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications. Toxins (Basel)8:77.